Gastrointestinal side effects such as nausea, vomiting, and diarrhoeawhich are common with GLP-1 medicationscan contribute to dehydration, electrolyte imbalances, and general malaise
In a clinical trial in pediatric patients aged 12 years and older with normal baseline heart rate, more patients treated with WEGOVY compared to placebo had maximum changes in heart rate of 20 bpm or more (54% versus 39%) [see Adverse Reactions (6.1)]
Most peptide regimens used in obesity and metabolic research show good overall tolerability, but they still carry risks, particularly for patients with diabetes, cardiovascular disease, or cancer history
(For all of last year, Mounjaro generated $482.5 million in revenues.) Based in Berkeley, CA, Carmot focuses on developing drugs for metabolic diseases that include obesity and diabetes, as well as Prader-Willi syndrome, the disease targeted by Carmots sole disclosed preclinical candidate CT-PYY, a long-acting PYY analog delivered as an injectable peptide
With Thursdays accelerated approval, Fabhalta is now indicated for patients with IgAN who are at risk of rapid disease progression, according to Novartis, defined as patients with a urine protein-to-creatinine ratio of at least 1.5 g/g
This is all a well-orchestrated assault on the compounded versions of their blockbuster molecule, semaglutide
